Insulin Delivery Devices Market To Reach USD 28.06 Billion By 2030 from Tushki Desale's blog

Insulin Delivery Devices Market Growth & Trends

The global insulin delivery devices market size was estimated at USD 28.06 billion in 2030 and is expected to grow at a CAGR of 7.89% from 2024 to 2030. Obesity, sedentary lifestyles, and unhealthy food habits, primarily in the young population, lead to the occurrence of diabetes. In addition, the growing diabetic geriatric population is another factor supporting the growth of this vertical. According to the United Nations, Department of Economic and Social Affairs, around 901 million individuals were aged 60 or over in 2015 and this number is projected to increase to 1.4 billion by 2030. Thus, the enlarging elderly population is expected to boost the demand for insulin delivery devices.

Technological advancements in diabetes management have significantly transformed insulin delivery methods, evolving from traditional injections to more advanced, minimally invasive techniques. Initially, insulin administration faced challenges in maintaining consistent blood glucose levels. However, the advent of insulin pens facilitated easier self-administration, reducing discomfort. The development of insulin pumps allowed for continuous insulin infusion, enhancing glucose control. A pivotal advancement was the introduction of Continuous Glucose Monitoring (CGM) devices, providing real-time glucose data, essential for informed decision-making. This set the stage for Artificial Pancreas Systems (APS), which integrate CGM data with insulin pumps for automated delivery, closely mimicking natural pancreatic function. Bionic technology, blending biological and artificial processes, has been instrumental in advancing insulin delivery. It underpins devices such as APS, utilizing algorithms, sensors, and automated pumps for precise blood sugar regulation, minimizing manual intervention. These innovations offer tailored, user-friendly solutions, notably improving patient outcomes. Modern insulin pumps, equipped with CGM integration, predictive algorithms, and smartphone connectivity, exemplify significant progress in device functionality, offering accurate and adaptable insulin management. These features not only mitigate risks associated with blood glucose extremes but also empower users with finer control over their insulin dosing, responding dynamically to glucose level changes.

Technological innovations and advancements are an ongoing trend in this vertical. The high demand for advanced insulin delivery devices is supporting the adoption of recently launched innovative pen devices and portable pumps, which is estimated to boost the market growth. Also, favorable reimbursement policies for these devices, mainly in developed countries like the U.S. and Germany, are anticipated to fuel the market growth during the study period. However, stringent regulatory requirements regulating the approval of insulin delivery devices and the high cost of insulin analogs in diabetes care management are major factors restraining the growth of this industry.

The market's prominent competitors are taking different initiatives such as acquisition, funding, and product development to expand their product portfolio and enhance their manufacturing capacity. For instance, in October 2021, Eli Lilly partnered with Cipla, to market its Insulin products (Humalog and Trulicity) in India. Additionally, In June 2021, the company acquired Protomer Technologies, to strengthen its market presence. Further, Novo Nordisk, joined hands with Biocorp to develop a Bluetooth-enabled smart add-on device for their pen insulin injector.

Request a free sample copy or view the report summary: https://www.grandviewresearch.com/industry-analysis/insulin-delivery-devices-market

Insulin Delivery Devices Market Report Highlights

• The insulin pens segment was the largest revenue-generating category of this market in 2021. The pen is equipped with self-contained cartridges and offers ease in handling and less pain while injecting insulin. The advantages of these pen devices over other products are resulting in their growing popularity, thus serving as a vital factor in contributing to the sectorb s highest share in this market
• The home care segment is estimated to be the fastest-growing segment due to increased adoption of self-care diabetes management devices and the availability of simplified and user-friendly product designs for patients
• North America is the leading regional sector and accounted for the largest revenue share in 2021 primarily due to the favorable reimbursement scenario in this space. Also, the presence of major manufacturers in this region is supporting market growth
• In Asia Pacific, the market is anticipated to grow fast during the forecast period. The high prevalence rate of diabetes in countries, such as China and India, is a major factor contributing to market expansion in this region

Insulin Delivery Devices Market Segmentation

Grand View Research has segmented the global insulin delivery devices market report based on product, end use, and region.

Insulin Delivery Devices Product Outlook (Revenue, USD Million, 2018 - 2030)

• Insulin Pens
  • Reusable Insulin Pens
  • Disposable Insulin Pens
• Insulin Pumps
  • Patch Pumps
  • Tethered Pumps
• Insulin Pen Needles
  • Standard Pen Needles
  • Safety Pen Needles
• Insulin Syringes
• Other Products

Insulin Delivery Devices End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics
• Homecare
• Other End Users

Insulin Delivery Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

List of Key Players in Insulin Delivery Devices Market

• Novo Nordisk A/S
• Sanofi
• Eli Lilly and Company
• Ypsomed AG
• Medtronic
• Insulet Corporation
• B. Braun SE
• Owen Mumford Ltd.
• Tandem Diabetes Care, Inc.
• BD (Becton, Dickinson, and Company)

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/insulin-delivery-devices-market